Grafeel Injection contains Filgrastim 300mcg, a recombinant granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of neutrophils in patients with neutropenia. It is primarily indicated for the treatment of neutropenia associated with chemotherapy, bone marrow transplantation, or severe chronic neutropenia. Filgrastim acts by binding to specific cell surface receptors on hematopoietic cells, promoting the proliferation, differentiation, and activation of neutrophil precursors, thereby reducing the duration of neutropenia and the risk of infection. Grafeel Injection is administered subcutaneously or intravenously, with dosing individualized based on patient response and clinical condition. Common adverse effects include bone pain, mild fever, and injection site reactions. It is contraindicated in patients with hypersensitivity to Filgrastim or any component of the formulation. Caution is advised in patients with sickle cell disease due to the risk of splenic rupture. Regular monitoring of complete blood counts is recommended during therapy to assess efficacy and adjust dosing. Grafeel Injection should be used under strict medical supervision, ensuring appropriate supportive care and infection control measures are in place. This product is essential in oncology and hematology settings to enhance patient outcomes by mitigating neutropenia-related complications.